Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Difamilast
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Otsuka Pharmaceutical
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Based upon FDA's recent guidance and the Company's successful End of Phase 2 Meeting, Medimetriks will also reduce the size of its MM36 (difamilast) Phase 3 pivotal trial program by approximately 80%.
Brand Name : MM36
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 18, 2020
Lead Product(s) : Difamilast
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Otsuka Pharmaceutical
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?